Home
overview

SMi Group is proud to announce the return of its 9th Annual Adaptive Designs in Clinical Trials conference on the 3rd - 4th April 2017 in London!

 


Since the recent advances and successes in adaptive platform clinical trials, there has been a rejuvenated interest into adaptive designed approaches. Adaptive designed approaches to clinical trials is an exciting area of biometrics and statistics for recent statistical and computational advances, and changes to regulatory frameworks have enabled more complex, robust and flexible clinical trials not previously offered by traditional clinical trial design.

 

This conference will highlight multiple topics within adaptive design encompassing the new approaches and trends amongst research and the industry. Topics will include the successes, strengths and pitfalls of key trends within drug development such as Bayesian Strategies, Seamless approaches, Dose-finding studies, and adaptive development programmes. It will also discuss pioneering research and industry-led case studies of adaptive designed clinical trials within key therapy areas, such as oncology, and the real life clinical and statistical adaptations these trials have led to.

Attend this conference to:

  • Learn about new adaptive design strategies to clinical trials, their strengths, pitfalls and future implications
  • Recognise current trends in adaptive design in clinical and platform trials
  • Understand how adaptive design approaches can offer flexibility and power to clinical trials
  • Understand how to use adaptive design to maximise trial cost effectiveness and reduce attrition
  • Gain an insight into new adaptive design strategies from real-life case studies in key therapy areas like Oncology
  • Hear about regulatory updates direct from regulatory bodies, and understand how to learn from these

Clinical trial managers & associates
Biostatisticians
Directors of business developement
Data managers
Senior statisticians
Professors of statistics
Directors of Clinical trials
Medical doctors
PhD students
Clinical scientists

 

Previous attendees included:

 

Accovion; Actelion Pharmaceuticals Ltd; Affibody; AstraZeneca; Bayer HealthCare; Bays Consulting; Berry Consultants, LLP; Bio Med Central; Boehringer-Ingelheim; Cancer Research UK; Cmed CRS Ltd; Cornell University; Daiichi Sankyo; DEBIOPHARM INTERNATIONAL SA; EMD Serono, Inc; Enterome; European Medicines Agency; European Medicines Agency (EMA); GW Pharmaceuticals; H. Lundbeck A/S; Highbury Regulatory Science; hVIVO Services Ltd; ICON Clinical Research; INSERM; Johnson & Johnson; king abdullah international medical research center ; MHRA; Orion Pharma; Pfizer Global Pharmaceuticals; Queen Mary, University of London; Rottapharm Biotech S.r.l.; Sandoz Biopharmaceuticals; Sanofi Aventis; Sanofi Pharma; Sigmaclinical; Synthon BV; The Cure Parkinsons Trust; UCL Cancer Institute; University Of Bath; University of Calgary; University of Pisa; Voisin Consulting Life Sciences; Warwick Medical School ;

Conference programme

8:30 Registration & Coffee

9:00 Chairman's Opening Remarks

Alex Sverdlov

Alex Sverdlov, Director, Statistical Scientist, Novartis
View Bio

9:10 Adaptive multi-arm randomisation approaches and methodology to clinical trials

Alex Sverdlov

Alex Sverdlov, Director, Statistical Scientist, Novartis
View Bio

  • Methodology for applying randomisation approaches to clinical trials
  • Applying multi-arm randomisation to drug development
  • Examples of randomisation application and methodology
  • 9:50 Hot topics and case studies in adaptive designs from a company’s perspective

    Frank Fleischer

    Frank Fleischer, Principal Methodology Statistician, Boehringer Ingelheim
    View Bio

  • Towards an adaptive platform based approach in oncology dose finding
  • Statistical Go / NoGos and alternative development pathways
  • Adaptive designs in the biosimilar framework
  • Case studies
  • 10:30 Morning Coffee & Networking Break

    11:00 Adaptive aspects in clinical development in Grünenthal

    Cecile Dubois

    Cecile Dubois, Head of Biostatistics, Grunenthal
    View Bio

  • Single trials with adaptive design vs adaptive nature of clinical development programs
  • Adaptive trial design aspects specific to indication pain/drug class opioids
  • Case studies of trials with adaptive designs in GRT
  • 11:40 Adaptive design: Historical perspective of how it arose

    John Warren

    John Warren, Director, Medicines Assessment Ltd
    View Bio

  • What was the old system?
  • Why was it insufficient?
  • What happens next?
  • 12:20 Networking Lunch

    13:30 Bayesian adaptive design in device development

    Giacomo Mordenti

    Giacomo Mordenti, Head of Global Biometrics, Livanova
    View Bio

  • The adaptive design of device clinical trials
  • Operational and logistical pitfalls common in device development
  • Important differences to consider between adaptive device and drug development
  • Case studies of Bayesian statistics in practise in devices
  • 14:10 Adaptive clinical development: From patient to market

    Michael Davies

    Michael Davies, Co-Founder & Chief Medical Officer, Blueberry Therapeutics
    View Bio

  • Adaptive clinical designs can speed development and cut costs
  • Upfront effort is required
  • Talk to the regulators about your ideas
  • 14:50 Testing a secondary endpoint after a group sequential test

    Christopher Jennison

    Christopher Jennison, Professor of Statistics, University Of Bath
    View Bio

  • Inference after a group sequential test needs care
  • Some plausible looking methods are not actually valid
  • We describe a general framework for multiple testing in the group sequential setting
  • We discuss testing a secondary hypothesis after stopping to reject the primary null hypothesis
  • 15:30 Chairman’s Closing Remarks and Close of Day One

    15:40 Afternoon Tea & Networking

    8:30 Registration & Coffee

    9:00 Chairman's Opening Remarks

    James Matcham

    James Matcham, Head of Biometrics, Early Clinical Development, AstraZeneca
    View Bio

    9:10 Building an adaptive design capability in early development

    James Matcham

    James Matcham, Head of Biometrics, Early Clinical Development, AstraZeneca
    View Bio

    Describing the journey at AstraZeneca
    Building skills and confidence in designing adaptive clinical trials
    Implications for early phase decision making

    9:50 Adaptive designs: How preclinical, translational and big data can contribute to a better design

    Emmanuel Pham

    Emmanuel Pham, VP Biometrics, Ipsen
    View Bio

  • Adaptive design often require a model underlying hypotheses
  • Developing these model is not easy when lacking of internal clinical data
  • Preclinical (non-clinical) data can be very useful, but often require to use translational expertise to be used efficiently
  • Big Data is also an incredible source of knowledge, but requires also a careful management to be integrated in a model
     
  • 10:30 Morning Coffee & Networking Break

    11:00 Bayesian adaptive trials for medical device and pharmaceutical trials

    Tom Parke

    Tom Parke, Director of Software Solutions, Berry Consultants, LLP
    View Bio

  • The design, modelling and simulation of bayesian methods in drug and device clinical trials
  • Platform / Master protocol designs
  • Case studies of bayesian statistics in practise – the EPAD trial
  • Innovative adaptive design to address immediate threats – Ebola trial 2015
  • 11:40 Adaptive design to check the dose range of a dose-ranging study

    Simon Kirby

    Simon Kirby, Senior Director, Pfizer
    View Bio

    Studies of adaptive dose-ranging designs have not necessarily found advantages for adaptive designs however adaptive designs may have a role to play in checking that the dose range

  • The 3 parameter Emax model and empirical justification for focusing on this model
  • Adaptations to try to ensure that the dose range goes low enough and high enough
  • Simulation study
  • Results of simulation study
  • Conclusions
  • 12:20 Networking Lunch

    13:30 PANEL DISCUSSION: Adaptive designs in clinical trials from scientific advice to marketing authorisation: Lessons learnt from submissions to regulatory agencies

  • Analysis of the adaptive elements used in the design and their impact on trial success
  • Discussion of the potential regulatory concerns
  •  

     

    Alex Sverdlov

    Alex Sverdlov, Director, Statistical Scientist, Novartis
    View Bio

    Olivier Collignon

    Olivier Collignon, Seconded National Expert – European Medicines Agency (EMA), Luxembourg Institute of Health
    View Bio

    Emmanuel Pham

    Emmanuel Pham, VP Biometrics, Ipsen
    View Bio

    14:10 Enrichment designs in oncology

    Loic Darchy

    Loic Darchy, Head of Statistical Methodology Group, Sanofi R&D
    View Bio

  • Overview of enrichment designs in statistical literature
  • Opportunities and challenges of enrichment design in oncology target therapies and development
  • Case Studies for adaptive enrichment
  • 14:50 Afternoon Tea & Networking

    15:20 Adaptive dose finding designs in oncology early phase trials: An industry experience

    Bo Huang

    Bo Huang, Director of Biostatistics, Pfizer
    View Bio

  • Overview of adaptive early dose-finding studies
  • A time-to-event continual reassessment method with adaptive weight function incorporating cyclical data
  • The practical implications of adaptive design on Pfizer oncology drug development with two case studies
  • 16:00 ICH E9(R1) and adaptive designs

    Christine Fletcher

    Christine Fletcher, Executive Director Biostatistics, Amgen
    View Bio

  • Introduce the new estimand and sensitivity analysis framework
  • Consider if the new framework will impact the design, conduct, analysis and reporting of adaptive trials
  • Discuss whether any new unique challenges will be introduced by the framework
  • 16:40 Chairman’s Closing Remarks and Close of Day Two

    +

    FEATURED SPEAKERS

    Bo Huang

    Bo Huang

    Director of Biostatistics, Pfizer
    James Matcham

    James Matcham

    Head of Biometrics, Early Clinical Development, AstraZeneca
    John Warren

    John Warren

    Director, Medicines Assessment Ltd
    Michael Davies

    Michael Davies

    Co-Founder & Chief Medical Officer, Blueberry Therapeutics

    Alex Sverdlov

    Director, Statistical Scientist, Novartis
    Alex Sverdlov

    Alex Sverdlov has worked as a statistical scientist in biopharmaceutical industry since 2007, in such companies as Novartis, Merck Serono and Bristol-Myers Squibb. He handled clinical trials in neurodegenerative diseases, metabolic disorders, ophthalmology, immunology, and oncology. Alex has been involved in active research on adaptive designs for clinical trials to improve efficiency of drug development. He recently edited a book “Modern Adaptive Randomized Clinical Trials: Statistical and Practical Aspects” which was published by CRC Press in 2015. Alex holds PhD in Statistical Science from George Mason University.

    Bo Huang

    Director of Biostatistics, Pfizer
    Bo Huang

    Dr. Bo Huang is a Director of Biostatistics at Pfizer. Prior to joining Pfizer, Bo received his PhD in statistics from the University of Wisconsin-Madison. He has extensive drug development experiences across all stages of clinical trials and is currently working in the field of immuno-oncology. Beyond projects, Bo has approximately 30 publications in statistical and medical journals, authored 2 book chapters and contributed to over 40 external oral presentations. In addition, he currently holds a patent in the US on cancer research.

    Cecile Dubois

    Head of Biostatistics, Grunenthal
    Cecile Dubois

    I am Head of Biostatistics at Grünenthal in Aachen (Germany), a company I joined in 2011. My team is responsible for ensuring comprehensive statistical input to optimize Grünenthal Innovation from early development to submission and life cycle management. I have more than 25 years of experience as a biostatistician in clinical trials. Among other companies, I have worked at Merck Sharp & Dohme, UCB, GSK and Janssen Pharmaceutica (now Johnson & Johnson). I have experience in all four phases of clinical trials in areas such as allergy and asthma, cardiovascular, CNS, pain, inflammatory disease and osteoporosis. I have been involved in discussions with Health Authorities such as the EMEA, FDA and KIKO in Japan to develop clinical products. Additionally, I have supported NDA approvals for a number of products and have collaborated within and across various disciplines to deliver robust statistical analyses for the optimization of the labeling and approval of medical products.

    Christine Fletcher

    Executive Director Biostatistics, Amgen
    Christine Fletcher

    Chrissie is a Regional Head in Global Biostatistical Science at Amgen and she leads a Health Technology Assessment (HTA) Biostatistics group. Chrissie has worked in the Pharmaceutical Industry for over 25 years and has experience of developing and commercialising new medicines from a variety of therapeutic areas across all phases of clinical development.

    Chrissie is currently the Vice-President of the European Federation of Statisticians in the Pharmaceutical Industry (EFSPI), and co-chair of the Clinical Development Expert Group for the European Federation of Pharmaceutical Industries and Associations (EFPIA).

    Chrissie is a Chartered Statistician and Chartered Scientist of the Royal Statistical Society (RSS). Chrissie has an MSc in Applied Statistics and a BSc (Hons) in Statistics with Management Science Techniques.
     

    Christopher Jennison

    Professor of Statistics, University Of Bath
    Christopher Jennison

    Christopher Jennison is Professor of Statistics at the University of Bath, UK. His PhD research at Cornell University concerned the sequential analysis of clinical trials and he has continued to work in this area for the past 30 years. His book with Professor Bruce Turnbull, "Group Sequential Methods with Applications to Clinical Trials", is a standard text on this topic and is widely used by practising statisticians.

    Professor Jennison's research is informed by experience of clinical trial analysis at the Dana Farber Cancer Institute, Boston and a broad range of consultancy with Medical Research institutes and Pharmaceutical companies.

    Emmanuel Pham

    VP Biometrics, Ipsen
    Emmanuel Pham

    MD and statistician, I have been working for French University, Public Hospital and French Agencies for 10 years (in Particular in Pharmacovigilance and Poison Centers) before joining the Pharmaceutical Industry. I have been working successively for Pierre Fabre, Gencell/Centelion (Spin-off from Aventis) and Sanofi-Aventis. I joined Ipsen in 2010 as Head of Research and Translational Biostatistics. I am now Vice-President Biometry, managing Statistics, Data-management and Medical Writing team Worldwide. My experience includes management of Data and Analysis for Project from Research, CMC, Toxicology, Clinical Trials, Post-Marketing Trials, Pharmacovigilance, Genomic, BioMarkers, and more.

    Frank Fleischer

    Principal Methodology Statistician, Boehringer Ingelheim
    Frank Fleischer

    After having studied mathematics as well as business mathematics in Milwaukee and Ulm, respectively, Frank has received his PhD in statistics from Ulm University in 2007. Afterwards he acted as a project statistician for several years mostly working in oncology, immunology and biosimilars. Currently he is part of the biostatistics group at Boehringer Ingelheim as a principal methodology statistician. In this role he is working on methodological questions regarding adaptive designs, dose finding and Bayesian statistics and is supporting several projects across different therapeutic areas.
    He has published several articles and book chapters on topics like multi-stage modelling in oncology, quality of central adjudication processes and spatial statistics. Apart from that he is giving lectures on topics like adaptive designs, Bayesian statistics and general clinical trial design.
     

    Giacomo Mordenti

    Head of Global Biometrics, Livanova
    Giacomo Mordenti

    After the degree in statistical sciences from the University of Florence (1998), Giacomo stared his career in drug development in Menarini where he was exposed to different therapeutic areas and development phases. In 2007 he moved to Geneva to join Merck Serono, where he lead a biostatistical team dedicated to early development in oncology. In 2013 Giacomo joined Grunenthal as global head of Biostatistics. In 2016 he moved to medical device industry in Livanova as Head of Global Biometrics. Since 2011 he is part of the scientific board of European Statistical Forum; since 2013 he is part of the European Statistical Leader group of EFSPI. His main research interests are in the field of Bayesian statistics, adaptive design and advanced safety analysis.

    James Matcham

    Head of Biometrics, Early Clinical Development, AstraZeneca
    James Matcham

    James Matcham joined AstraZeneca in November 2013 as the Head of Early Clinical Development Biometrics, where he has led the development of the group to specialise in early clinical trial design, decisions and analysis. After completing his MSc in Statistics at Imperial College, London, he began his career as a Research Fellow at the Applied Statistics Research Unit at the University of Kent, UK working for 5 years in various applications of statistics but particularly in the area of clinical cross-over trials, linear and non-linear modelling and Bayesian methods. He then completed 21 years at Amgen where he worked on the development and regulatory/reimbursement approval of many of their biotechnology products, representing the company at regulatory submissions in the US and the EU. His last few years there were spent working to improve literature review, the use of adaptive and early phase design, network meta-analysis, Bayesian methods and quantitative decision making.
    James is a Chartered Statistician of the Royal Statistical Society has been a member of UK society for Pharmaceutical Statisticians (PSI) for 30 years, serving on the Scientific and Training Committees as well as the Board of Directors. He has also served on the Professional Affairs Committee of the Royal Statistical Society and the Scientific Committee of the European Federation of Pharmaceutical Statisticians.

    John Warren

    Director, Medicines Assessment Ltd
    John Warren

    John Warren is a clinical scientist who established Medicines Assessment Ltd as a pharmaceutical consultancy in 2011 (www.medicinesassessment.com).
    He advises multiple pharmaceutical companies on clinical development.

    He trained in medicine at Guy’s Hospital, where he wrote a thesis on the human physiology of epinephrine. He worked for the UK Medicines Healthcare products Regulatory Agency (MHRA) as an Expert Medical Assessor from 1995-2010 evaluating new drug applications for Europe across the therapeutic spectrum. Member of the European Scientific Advice Working Party 2003-2010; Pharmacokinetic Subgroup of the Efficacy Working Party 2007-2008. He contributed to the EU Notes for Guidance on Asthma, COPD, ARDS and Bioequivalence. When appointed to the MHRA in 1995 he took a concomitant Honorary Senior Lectureship in Clinical Pharmacology at St Thomas' Hospital.

    Previously a Senior Lecturer at the National Heart and Lung Institute, with Honorary Consultant status at the Brompton, Charing Cross and Chelsea & Westminster Hospitals, 1990-1994. This followed a Senior Registrar post in Clinical Pharmacology at the Royal Postgraduate Medical School 1986-1990.

    Specialist UK accreditation was granted in General Medicine, Clinical Pharmacology and Cardiology. He is the author of over 100 publications on pharmacology and a book on the Endothelium.

    Guest speaker at the 2010 Annual Austrian Pharmacological Society meeting. British Pharmacology Society Speaker/Visitor at the 2013 Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists. For a review of drug development please see "Drug Discovery: Lessons from Evolution" BJCP 2011;71:497-503.

    Previously a Member of the Editorial Board of Clinical Pharmacology & Therapeutics and Microvascular Research. Currently Executive Editor for British J Clinical Pharmacology and member of the Joint Speciality Committee for Clinical Pharmacology of the Royal College of Physicians, London.
     

    Loic Darchy

    Head of Statistical Methodology Group, Sanofi R&D
    Loic Darchy

    Loïc has been working in the pharmaceutical industry for almost 30 years in various companies. He held senior statistician positions, management positions in Biostatistics and more recently he switched to the statistical expertise field as head of statistical methodology group at Sanofi &D. He is located in Paris. His favorite research topics are adaptive designs (especially adaptive population enrichment designs and biomarker-based designs), handling of multiplicity in clinical trials, missing data, meta-analyses, dose-finding designs and analyses and use of data learning techniques for clinical development.

    Michael Davies

    Co-Founder & Chief Medical Officer, Blueberry Therapeutics
    Michael Davies

    Mike Davies is an experienced and competent professional with a significant record in all Phases of drug development whose career development to date has been achieved through an inherent thirst for knowledge and desire to achieve high impacting results that continually make a difference. Mike is the co-founder of Blueberry Therapeutics a company focussed on the nano-formulation of drugs and peptides to treat infection and inflammation. Mike has taken Blueberry’s first compound into clinic development utilising a regulatory “approved adaptive process” with the aim of reaching NDA within 3 years. Mike can be contacted at www.blueberrytherapeutics.com

    Olivier Collignon

    Seconded National Expert – European Medicines Agency (EMA), Luxembourg Institute of Health
    Olivier Collignon

    Dr Olivier Collignon is statistics consultant for researchers at LIH and external groups.

    He is currently seconded at the European Medicines Agency in London, where he participates to the scientific evaluation of the design and results of clinical trials to obtain marketing authorization of new drugs in Europe. He is especially interested in adaptive designs and the use of historical controls.

    His expertise also consists in developing variable selection algorithms and supervised classification methods to help biologists find new biomarkers and risk factors of different diseases, especially in cardiology and oncology. Dr Collignon has been involved in the National Cancer Registry of Luxembourg.
     

    Simon Kirby

    Senior Director, Pfizer
    Simon Kirby

    Simon Kirby is a Senior Director in the Statistical Research and Consulting Centre at Pfizer. He has worked for Pfizer for more than 17 years after previously holding the position of Principal Lecturer in Statistics at Liverpool John Moores University. He has also previously worked as a Statistician at the Institute of Food Research in the UK, Rothamsted and Revlon Healthcare. Simon has undergraduate degrees in Economics and Economic Policy and Mathematics and MSc and PhD degrees in Statistics.

    Tom Parke

    Director of Software Solutions, Berry Consultants, LLP
    Tom Parke

    Tom Parke is Director of Software Solutions for Berry Consultants. Tom’s passion and experience has been software for adaptive clinical trials. Prior to joining Berry Consultants, he was Head of Clinical Trial Solutions for Tessella Ltd. While at Tessella for nearly 20 years, he managed the development and running of the software system to support Pfizer’s ASTIN Stroke trial, and has setup multiple software systems to support different aspects of many adaptive clinical trials, mostly designed by Berry Consultants. In parallel, he managed projects to develop clinical trial simulators, first with Pfizer, then Wyeth, before acting as the expert advisor and reviewer to the joint development of FACTS with Berry Consultants. Prior to working at Tessella, he worked for Inmos, Imperial Software Technology, and Praxis on compilers, operating systems and real time control systems. He graduated with a Joint First Class Honours in Math and Computer Science from Bristol University in 1979.

    Official Media Partner

    Official Publication

    Supporters

    VENUE

    Copthorne Tara Hotel

    Scarsdale Place, Kensington, London, United Kingdom

    The Copthorne Tara Hotel London Kensington is an elegant contemporary four-star hotel in prestigious Kensington, located just a two minutes walk from High Street Kensington underground station, making exploring easy. The hotel offers well-appointed and comfortable guest rooms combining Standard, Superior and Club accommodation. Club rooms offer iconic views over the city and include Club Lounge access for complimentary breakfast and refreshments. Guests can sample the authentic Singaporean, Malaysian and Chinese cuisine at Bugis Street, traditional pub fare at the Brasserie Restaurant & Bar or relax with a delicious drink at West8 Cocktail Lounge & Bar.

    The Copthorne Tara Hotel boasts 745 square meters of flexible meeting space, consisting of the Shannon Suite and the Liffey Suite, ideal for hosting conferences, weddings and social events. Facilities include access to the business centre 24 hours a day, fully equipped fitness room, gift shop, theatre desk and Bureau de Change. With ample onsite parking outside the London congestion charge zone and excellent transport links via Heathrow Airport, the hotel is the perfect location for business or leisure stays. The hotel is within close proximity to the shops of High Street Kensington, Knightsbridge and Westfield London, Olympia Conference Centre, Royal Albert Hall, Kensington Palace and Hyde Park.

     

    HOTEL BOOKING FORM

    Interview with Bo Huang, Director of Biostatistics, Pfizer

    Download

    Interview with Alex Sverdlov, Director, Novartis

    Download

    Media Partners


    Cutting Edge

    Official Media Partner
    http://www.cuttingedgeinfo.com

    Cutting Edge Information provides customized research and benchmarking reports to pharmaceutical, biotechnology and other life science companies. We provide off-the-shelf and customized research for key areas including medical affairs, clinical development, market access, regulatory affairs, marketing management, sales and HCP fair market value.

    Media Partners


    International Journal of Medical Engineering and Informatics

    Official Publication
    http://www.inderscience.com/ijmei

    IJMEI promotes an understanding of the structural/functional aspects of disease mechanisms and the application of technology towards the treatment/management of such diseases. It seeks to promote interdisciplinary collaboration between those interested in the theoretical and clinical aspects of medicine and to foster the application of computers and mathematics to problems arising from medical sciences. IJMEI includes authoritative review papers, the reporting of original research, and evaluation reports of new/existing techniques and devices. Each issue also contains a comprehensive information service.


    International Journal of Computational Biology and Drug Design

    Official Publication
    http://www.inderscience.com/ijcbdd

    IJCBDD, an International Society of Intelligent Biological Medicine official journal, bridges the gap between two very important, complementary disciplines, computational biology and drug design. Through advances in high-throughput genome sequencing and digital imaging technologies, biocomputing, drug design and medical research have unfolded new, predictive sciences such as genomics, proteomics, lipidomics, metabolomics, cytomics and pharmaconomics. These promote new computational, statistical and biomedical approaches to drug design/development, besides unleashing the potential of significantly more accurate, effective personalised diagnosis, therapeutics and patient care.


    International Journal of Functional Informatics and Personalised Medicine

    Official Publication
    www.inderscience.com/ijfipm

    Functional informatics and personalised medicine in the new era of biomedical sciences and computational sciences are interactive disciplines that hold great promise for the advancement of cutting-edge research and development in biomedical informatics and pharmaceutical sciences. IJFIPM is dedicated to promoting the research, education and awareness of functional informatics and personalised medicine, and provides a common platform for the cross-fertilisation of ideas by bridging important and complementary disciplines into an interactive and attractive forum.


    International Journal of Biomedical Engineering and Technology

    Official Publication
    http://www.inderscience.com/ijbet

    IJBET addresses cutting-edge research in the multi-disciplinary area of biomedical engineering and technology. Medical science incorporates scientific/technological advances combining to produce more accurate diagnoses, effective treatments with fewer side effects, and improved ability to prevent disease and provide superior-quality healthcare. A key field here is biomedical engineering/technology, offering a synthesis of physical, chemical, mathematical and computational sciences combined with engineering principles to enhance R&D in biology, medicine, behaviour, and health. IJBET includes the Asia-Pacific Chapter in Biomedical Wireless Technology (APC-BWT).


    Int. J. of Biotechnology

    Official Publication
    http://www.inderscience.com/ijbt

    IJBT provides an international forum and refereed authoritative source of information in the field of Biotechnology and Biotechnics, with emphasis on management and economics, as well as the political and social issues. It aims to disseminate knowledge, provide a learned reference in the field, and establish channels of communication between academic and research experts, policy makers and executives in industry, commerce and investment institutions.


    International Journal of Bioinformatics Research and Applications

    Official Publication
    http://www.inderscience.com/ijbra

    Bioinformatics is an interdisciplinary research field that combines biology, computer science, mathematics and statistics into a broad-based field that will have profound impacts on all fields of biology. The emphasis of IJBRA is on basic bioinformatics research methods, tool development, performance evaluation and their applications in biology. IJBRA addresses the most innovative developments, research issues and solutions in bioinformatics and computational biology and their applications.

    Media Partners


    Labhoo

    Supporters
    http://www.labhoo.com



    Labsave

    Supporters
    http://www.labsave.com

    Labsave is the leading savings website for Laboratory Equipment and Lab Supplies. We work closely with the top suppliers in the world to bring you the best products at the most competitive prices. We are constantly striving to secure the biggest and most exclusive offers that you won’t find anywhere else! http://www.labsave.com/


    Pharmacircle

    Supporters
    http://www.pharmacircle.com

    PharmaCircle is an innovative knowledge management company serving the current and future global leaders in the Pharmaceutical and Biotechnology related industries. PharmaCircle is a one stop information and analysis source for pipeline, products, clinical trials, drug delivery technologies, deals and acquisitions, company financials, venture capital investments, product sales, pharmaceutical services, news, patents and more….


    Drug Discovery Today

    Supporters
    http://www.drugdiscoverytoday.com/

    Drug Discovery Today is one of the most cited review journals in the field of drug discovery, with an impact factor of 6.422.
    Drug Discovery Today will benefit your research by helping to keep you up-to-date with all of the fast-moving and emerging topics in drug discovery. Each issue is packed full of the latest research news, peer-reviewed articles and comment and opinion from leading research scientists.


    evvnt Ltd

    Supporters
    http://www.evvnt.com

    evvnt enables people all over the world to fill their events utilising the most effective event listing sites on the web. Every minute, with little more than a click, more events and conferences appear in listings, in search engines and on mobile - discoverable by both category and location. With next to no effort customers of evvnt get better attendance, while consumers find events they previously had no idea existed. To date customers in 70 countries worldwide have submitted over 500,000 thousand event listings, created over 300,000 live links, and generated 1 million clicks to ticketing and registration pages. Learn more at www.evvnt.com


    Pharmavision

    Supporters
    http://www.pharmavision.co.uk

    PharmaVision offers a consultancy service providing independent pharmaceutical thematic research to the healthcare industry, the investment community and competitive intelligence specialists. We perform due diligence research and provide expert commentary in healthcare. Our reports combine scientific analysis in drug delivery, R&D technologies and pharmaceutical products including patient modelling, product/technology forecasts and market trends evaluation.


    Swiss Biotech Association

    Supporters
    http://www.swissbiotech.org/

    The Swiss Biotech Association (SBA) is the national industry association for biotechnology, including pharmaceuticals, diagnostics, agriculture, food, cosmetics, environmental biotechnology, and specialty chemicals. Members are companies active in modern biotechnology, such as R&D, Production, Marketing and Sales, Finance, Services and Consulting. SBA provides a networking platform for Life Science clusters, academic and federal institutions the like. Founded in March 1998, the Association grows steadily.


    GaBI

    Supporters
    http://www.gabionline.net

    Generics and Biosimilars Initiative (GaBI) was founded in 2008. GaBI aims to foster the worldwide efficient use of high quality and safe medicines at an affordable price, thus advancing and supporting the idea of accessible, affordable and sustainable health care. The objective of GaBI is to raise the scientific status of generic and biosimilar medicines, via well-documented and up-to-date information about generic and biosimilar medicines both in print (www.gabi-journal.net) and electronically (www.gabionline.net) in an open access format, providing high quality, scientifically sound and reliable information to healthcare professionals including physicians, pharmacists and nurses, consumers, drug developers, third-party payers, legislators and assessors; who are in need of a reliable, critical and independent source of information on all aspects of generic and biosimilar medicines. Subscribe to gain easy access of information on the latest scientific research and developments in generic and biosimilar medicines via GaBI Online to editorial@gabionline.net; or submit a manuscript to GaBI Journal to editorial@gabi-journal.net. GaBI’s mission – Building trust in cost-effective treatments


    Biosave

    Supporters
    http://www.Biosave.com

    Biosave.com brings together the best Life Science promotions, product releases, featured products, publications, videos and events from 100’s of leading Life Science suppliers. Updated 24 hours a day, Biosave is constantly uploading special promotions and exciting product news that you won’t find anywhere else. Our goal is to provide our users with the most exclusive product information to help reach that all important purchasing decision.


    Farmavita

    Supporters
    http://www.farmavita.net/

    Farmavita Net is professional community and network of pharmaceutical licensing and business development executives, innovators and researchers
    Farmavita.Net is the pharmaceutical licensing, technology transfer and regulatory affairs network. We are managing the marketplace of offers and demand for pharmaceutical Dossiers, know-how and technologies. Members of Farmavita.Net network usually find a number of attractive solutions for business development, alliances, joint ventures, co-development and co-marketing of pharmaceutical products. Farmavita.Net is not just a pure Internet portal. We manage a number of regional associates. We are connecting the dynamic network of few hundreds members / pharmaceutical companies interested in license-in and license-out opportunities.


    CanBiotech

    Supporters
    http://www.canbiotech.com

    CanBiotech - A Portal and B2B Outsourcing Marketplace for the Biotech and Pharmaceutical Industry. The Marketplace features the Outsourcing Services Showcase; the Portal features our biopharmaceutical and venture capital directories and databases. Publications include the BioMedical Outsourcing Report and the Bio Outsourcing Asia© Publication.


    Biocompare

    Supporters
    http://www.biocompare.com

    Biocompare.com is the leading resource for up-to-date product information, product reviews, and new technologies for life scientists. Biocompare combines an in-depth knowledge of life science products and new technologies with the power of the Internet to offer scientists the most dynamic, relevant, and innovative media-based marketplace for life science information.


    Absave

    Supporters
    http://www.absave.com

    Absave.com is the leading savings website for Antibodies and Immunological Products. Search our extensive database of Antibodies, Kits, Proteins & Peptides, Reagents, etc. to find the best savings!


    BioChem Adda

    Supporters
    https://www.biochemadda.com/

    BioChem Adda is a Not-just-for-Profit organization which aims to bring out the most reliable and transparent information about everything related to jobs, careers, education, news, articles, and events from the field of BioSciences and Chemistry!


    Pharmaceutical Technology

    Supporters
    http://www.pharmaceutical-technology.com

    Pharmaceutical-technology.com is the only website focusing specifically on issues relevant to pharmaceutical professionals working with technology, be it development, engineering, IT or production. Pharmaceutical-technology.com brings you the latest in industry projects and updates, along with the news, views and trends that leading professionals – from senior executives to manufacturing managers and heads of procurement – require to stay on top of their field.


    Technology Networks

    Supporters
    http://www.technologynetworks.com

    Founded in 2000, Technology Networks is established as the leading news provider for life science and drug discovery professionals. In addition, we provide unique content including webcasts, videos, application notes and posters from recent conferences. Our portfolio now includes around 30 focussed scientific communities, all of which are accessible free of charge within TechnologyNetworks.com


    Mednous

    Supporters
    http://www.MedNous.com

    MedNous is a print publication and website about medical innovation in Europe. It carries exclusive interviews with companies that are at the forefront of medical technology, as well as contributor articles from prominent practitioners. Our mission is to identify significant advances in medicine and to explain how this innovation is being commercialised. In doing so, we talk to venture capitalists about what products and platforms they are supporting. We report on how regulators cope with the accelerating pace of innovation. And we regularly cover the latest developments in the discovery and development of new medical concepts in the area of antibodies, vaccines, small molecules, regenerative medicine and nanomedicines. MedNous combines the English word for medicine with the Greek word for intellect. And those with nous are readers of our publication. Visit our website: www.mednous.com


    Select Science

    Supporters
    http://www.selectscience.net/

    SelectScience is an independent, online information resource for the worldwide scientific community, and the home of trusted information for laboratory scientists. Discover impartial, expert opinion and trusted reviews about latest laboratory equipment and techniques; plus videos, application notes and science news from around the world. Become a member for free today.


    Medical News Today

    Supporters
    http://www.medicalnewstoday.com

    Medical News Today is the largest independent medical and health news site on the web - with over 10,000,000 monthly unique users it is ranked number one for medical news on all major search engines. Medical News Today is used by pharmaceutical, biotech and health organizations, advertising agencies, PR companies and vertical ad networks to deliver targeted campaigns to HCPs, patients and caregivers. To find out how Medical News Today can help you to reach the right audience contact peter@medicalnewstoday.com or visit www.medicalnewstoday.com.


    Inderscience Publishers

    Supporters
    http://www.inderscience.com

    Inderscience is a dynamic, leading, independent journal publisher. The company disseminates the latest research across the broad fields of science, engineering and technology; management, public and business administration; environment, ecological economics and sustainable development; computing, ICT and internet/web services, and related areas. Inderscience offers over 35 years' experience in publishing and has succeeded in building a substantial collection approaching 400 high-quality peer-reviewed international research journals in both online and print formats. We offer a variety of ways to keep up-to-date with the latest published leading-edge research while our online collection represents a fully-searchable digital archive of around 60,000 articles.


    PharmaVOICE

    Supporters
    http://www.pharmavoice.com

    PharmaVOICE magazine, and its supporting VIEW publications, provide commentary about the challenges and trends impacting the life-sciences industry, covering a range of issues from molecule through market. PharmaVOICE's more than 41,000 U.S.-based subscribers are also kept abreast of the latest trends through additional media resources, including WebSeminars, Podcasts, Videocasts, and White Papers.

    SAVE TO


    Outlook Calendar  OUTLOOK CALENDAR
    Google Calendar  GOOGLE CALENDAR
    ICal Calendar  ICAL CALENDAR
    Yahoo! Calendar  YAHOO! CALENDAR

    Copthorne Tara Hotel

    Scarsdale Place
    Kensington
    London W8 5SR
    United Kingdom

    Copthorne Tara Hotel

    The Copthorne Tara Hotel London Kensington is an elegant contemporary four-star hotel in prestigious Kensington, located just a two minutes walk from High Street Kensington underground station, making exploring easy. The hotel offers well-appointed and comfortable guest rooms combining Standard, Superior and Club accommodation. Club rooms offer iconic views over the city and include Club Lounge access for complimentary breakfast and refreshments. Guests can sample the authentic Singaporean, Malaysian and Chinese cuisine at Bugis Street, traditional pub fare at the Brasserie Restaurant & Bar or relax with a delicious drink at West8 Cocktail Lounge & Bar.

    The Copthorne Tara Hotel boasts 745 square meters of flexible meeting space, consisting of the Shannon Suite and the Liffey Suite, ideal for hosting conferences, weddings and social events. Facilities include access to the business centre 24 hours a day, fully equipped fitness room, gift shop, theatre desk and Bureau de Change. With ample onsite parking outside the London congestion charge zone and excellent transport links via Heathrow Airport, the hotel is the perfect location for business or leisure stays. The hotel is within close proximity to the shops of High Street Kensington, Knightsbridge and Westfield London, Olympia Conference Centre, Royal Albert Hall, Kensington Palace and Hyde Park.

     

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.